Although bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF), has received FDA approval for treating recurrent GBM, its effectiveness in progressive GBM after initial therapy remains limited2–5. The gene discussed is VEGFA; the disease is glioblastoma.